Vaginal estrogen treatments are increasingly recognized as an effective and safe option for addressing common menopause-related symptoms such as vaginal dryness, pelvic pain, and urinary tract infections. These symptoms, collectively known as genitourinary syndrome of menopause (G.S.M.), stem from the natural decline in estrogen levels experienced by women during middle age.

The available vaginal estrogen products—which include creams, rings, and tablets inserted directly into the vagina—work by restoring moisture and elasticity to vaginal tissue. This can relieve discomfort during sex or everyday activities, as well as reduce the frequency and urgency of urination. Additionally, vaginal estrogen helps maintain vaginal acidity and promotes the growth of beneficial bacteria, which can reduce the risk of infections that might otherwise spread to the kidneys.

The U.S. Food and Drug Administration (FDA) removed a black box warning from estrogen products, including vaginal formulations, last year. This warning had previously cautioned users about increased risks of cancer and blood clots, contributing to widespread hesitancy about hormonal treatments. Experts now emphasize that vaginal estrogen poses a much lower risk in this regard compared to systemic hormone therapies, and even patients at high risk for blood clots can often use vaginal estrogen safely.

Despite its benefits and safety profile, vaginal estrogen remains underused. Studies have shown that only a small percentage of eligible patients receive prescriptions for these treatments. One analysis of Medicare recipients with a diagnosis related to G.S.M. found that just 9 percent filled a vaginal estrogen prescription. Another study reported that 71 percent of patients with the condition did not receive any treatment.

Healthcare professionals point to underdiagnosis and lack of patient awareness as key factors in this treatment gap. Some women may not report symptoms or recognize their severity until they undergo a physical exam. Physicians often recommend initiating vaginal estrogen at early signs of tissue changes to prevent progression to more severe dysfunction.

While vaginal estrogen is generally considered appropriate for most postmenopausal women, those undergoing treatment for estrogen-sensitive cancers may need to avoid or modify use. However, many patients who have completed cancer treatment can safely use low-dose vaginal estrogen products under medical supervision.

Clinicians are increasingly advocating for a proactive approach to managing G.S.M., emphasizing that early intervention with vaginal estrogen can improve quality of life and prevent more serious complications related to the menopause transition.